Phase I/II Trial of Multitargeted Tyrosine Kinase Inhibitor Sunitinib in Combination with Image-guided Radiotherapy for Patients with Oligometastases

Phase II study of sunitinib malate, a mu

Phase II study of sunitinib malate, a multitargeted tyrosine kinase inhibitor in patients with relapsed or refractory soft tissue sarcomas. Focus on three prevalent histologies: Leiomyosarcoma, liposarcoma and malignant fibrous histiocytoma

✍ S. Tariq Mahmood; Samuel Agresta; Carlos E. Vigil; Xiuhua Zhao; Gang Han; Gina D 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 French ⚖ 251 KB

## Abstract Soft tissue sarcomas (STS) represent a diverse group of histologic subtypes with targetable molecular alterations, often treated as a single disease. Sunitinib malate is a multitargeted receptor tyrosine kinase inhibitor active in other solid tumors carrying similar alterations (__i.e._